Newmark Group, Inc.
$3.20B- Market cap
- $2.75B
- Debt
- +$671.75M
- Cash
- −$229.11M
Capital structure 80% equity / 20% debt · EV / Revenue 0.97x · EV / EBITDA 10.50x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NMRK stock price vs ZNTL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZNTL's multiple
Needs ZNTL P/E.
Implied fair value · at NMRK's multiple
Needs EPS (TTM) is negative, NMRK P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NMRK FY 2025 (ended Dec 31, 2025) · ZNTL FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 80% equity / 20% debt · EV / Revenue 0.97x · EV / EBITDA 10.50x
Capital structure 78% equity / 22% debt · EV / Revenue 4.96x
NMRK carries the larger enterprise value at $3.20B against $334.64M; NMRK trades on the lower EV / Revenue multiple (0.97x vs 4.96x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NEWMARK GROUP, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.46x
0.24x
Net debt / EBITDA
Leverage against operating earnings
1.45x
-0.29x
Cash and equivalents
Liquid reserves on the balance sheet
$229.11M
$33.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JONES LANG LASALLE INC
NMRK vs JLL
Cushman & Wakefield plc
NMRK vs CWK
Marcus & Millichap, Inc.
NMRK vs MMI
CBRE GROUP, INC.
NMRK vs CBRE
Arcus Biosciences, Inc.
NMRK vs RCUS
Repare Therapeutics Inc.
NMRK vs RPTX
IDEAYA Biosciences, Inc.
NMRK vs IDYA
Mersana Therapeutics, Inc.
NMRK vs MRSN
EXELIXIS, INC.
NMRK vs EXEL
$671.75M
$82.57M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.